HINT1 mutations define a novel disease entity - autosomal recessive axonal neuropathy with neuromyotonia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease.NPJ Parkinson's disease · 2022
   Article
2. Second messenger ApNature communications · 2019
   Article
3. Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.Oncogene · 2017
   Article
4. Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy among Czech patients and neuromyotonia is rather an underdiagnosed symptom.Neurogenetics · 2015
   Article

Corrections and comments

• Comment on
  Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.